Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

RTP-801i for wet AMD begins phase I study

Feb. 6, 2007

CF-101 studied for dry eye syndrome in new phase II study

Feb. 6, 2007

ATG-3 completes phase I study for wet AMD

Feb. 2, 2007

Recent Dainippon Sumitomo patent discloses novel treatment option for glaucoma

Feb. 2, 2007

Increasing omega-3 fatty acid intake decreases age-related IOP elevation

Jan. 29, 2007

Positive phase III findings for Akten in ocular anesthesia

Jan. 25, 2007

E.U. approval for Lucentis in wet AMD

Jan. 24, 2007

Enrollment begins in phase III ophthalmic trials of difluprednate

Jan. 24, 2007

IND accepted for iCo-007 in diabetic macular edema

Jan. 24, 2007

Synergistic effects of triple antiangiogenic therapy in preclinical models of neovascularization

Jan. 23, 2007

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...